Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution

PLoS Neglected Tropical Diseases

Volumn 3, Issue 8, 2009, Pages

  Lakew, Takele ^a   Alemayehu, Wondu ^a   Melese, Muluken ^a   Yi, Elizabeth ^b   House, Jenafir I ^b   Hong, Kevin C ^b   Zhou, Zhaoxia ^b   Ray, Kathryn J ^b   Porco, Travis C ^b   Gaynor, Bruce D ^b,c   Lietman, Thomas M ^b,c   Keenan, Jeremy D ^b,c  

^a ORBIS INTERNATIONAL   (Ethiopia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; TETRACYCLINE;

ARTICLE; CHILD; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDEMIC DISEASE; ETHIOPIA; EYE INFECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PREVALENCE; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TRACHOMA; TREATMENT RESPONSE;

EID: 70449507135     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000507     Document Type: Article

References (32)

1. Solomon AW, Zondervan M, Kuper H, Buchan JC, Mabey DCW, et al. (2006) Trachoma control: a guide for programme managers. Geneva: World Health Organization.
2. Bailey RL, Arullendran P, Whittle HC, Mabey DC (1993) Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 342: 453-456. (Pubitemid 23240308)
3. Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, et al. (1997) A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis 24: 363-368. (Pubitemid 27096789)
4. Schachter J, West SK, Mabey D, Dawson CR, Bobo L, et al. (1999) Azithromycin in control of trachoma. Lancet 354: 630-635.
5. West SK, Munoz B, Mkocha H, Holland MJ, Aguirre A, et al. (2005) Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 366: 1296-1300. (Pubitemid 41416585)
6. Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, et al. (2006) Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA 295: 1142-1146. (Pubitemid 43352343)
7. Melese M, Chidambaram JD, Alemayehu W, Lee DC, Yi EH, et al. (2004) Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA 292: 721-725. (Pubitemid 39062527)
8. Lietman T, Porco T, Dawson C, Blower S (1999) Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 5: 572-576.
9. Ray KJ, Porco TC, Hong KC, Lee DC, Alemayehu W, et al. (2007) A rationale for continuing mass antibiotic distributions for trachoma. BMC Infect Dis 7: 91. (Pubitemid 47470233)
10. Solomon AW, Harding-Esch E, Alexander ND, Aguirre A, Holland MJ, et al. (2008) Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med 358: 1870-1871. (Pubitemid 351581223)
11. Gill DA, Lakew T, Alemayehu W, Melese M, Zhou Z, et al. (2008) Complete elimination is a difficult goal for trachoma programs in severely affected communities. Clin Infect Dis 46: 564-566. (Pubitemid 351263496)
12. West S, Munoz B, Mkocha H, Gaydos C, Quinn T (2007) Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Invest Ophthalmol Vis Sci 48: 1492-1497. (Pubitemid 351261330)
13. Melese M, Alemayehu W, Lakew T, Yi E, House J, et al. (2008) Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 299: 778-784. (Pubitemid 351281571)
14. Lakew T, House J, Hong KC, Yi E, Alemayehu W, et al. (2009) Reduction and return of infectious trachoma in severely affected communities in ethiopia. PLoS Negl Trop Dis 3: e376.
15. Peeling RW, Toye B, Jessamine P, Gemmill I (1998) Pooling of urine specimens for PCR testing: a cost saving strategy for Chlamydia trachomatis control programmes. Sex Transm Infect 74: 66-70. (Pubitemid 28201985)
16. Diamant J, Benis R, Schachter J, Moncada J, Pang F, et al. (2001) Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection. Ophthalmic Epidemiol 8: 109-117. (Pubitemid 32692555)
17. Morre SA, van Dijk R, Meijer CJ, van den Brule AJ, Kjaer SK, et al. (2001) Pooling cervical swabs for detection of Chlamydia trachomatis by PCR: sensitivity, dilution, inhibition, and cost-saving aspects. J Clin Microbiol 39: 2375-2376.
18. Davidson R, MacKinnon JG (1993) Estimation and inference in econometrics. New York: Oxford University Press. pp 552-556.
19. Anderson RM, May RM (1991) Infectious diseases of humans : dynamics and control. Oxford; New York: Oxford University Press. pp 87-121.
20. Ali M, Emch M, Yunus M, Sack D, Lopez AL, et al. (2008) Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. Pediatr Infect Dis J 27: 33-37.
21. Lynch M, West S, Munoz B, Frick KD, Mkocha HA (2003) Azithromycin treatment coverage in Tanzanian children using community volunteers. Ophthalmic Epidemiol 10: 167-175. (Pubitemid 36819673)
22. Lietman T, Porco T, Dawson C, Blower S (1999) Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 5: 572-576.
23. Solomon AW, Foster A, Mabey DCW (2005) Single Dose Azithromycin for Trachoma: Author Reply. New Engl J Med 352: 414-415.
24. Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, et al. (2004) Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 351: 1962-1971. (Pubitemid 39447137)
25. Emerson PM, Burton M, Solomon AW, Bailey R, Mabey D (2006) The SAFE strategy for trachoma control: Using operational research for policy, planning and implementation. Bull World Health Organ 84: 613-619. (Pubitemid 44338245)
26. Shah NAHJ, Lakew T, Alemayehu W, Halfpenny C, Hong KC, Porco TC, Whitcher JP, Lietman TM, Gaynor BD (in press) Travel and implications for the elimination of trachoma in Ethiopia. Ophthalmic Epidemiol.
27. Zhang J, Lietman T, Olinger L, Miao Y, Stephens RS (2004) Genetic diversity of Chlamydia trachomatis and the prevalence of trachoma. Pediatr Infect Dis J 23: 217-220. (Pubitemid 38332645)
28. House J, Gaynor B, Taylor H, Lietman TM (2007) The real challenge: can we discover why trachoma is disappearing before it's gone? Int Ophthalmol Clin 47: 63-76.
29. Burton MJ, Holland MJ, Makalo P, Aryee EA, Alexander ND, et al. (2005) Reemergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet 365: 1321-1328. (Pubitemid 40501294)
30. Gaynor BD, Miao Y, Cevallos V, Jha H, Chaudary JS, et al. (2003) Eliminating trachoma in areas with limited disease. Emerg Infect Dis 9: 596-598. (Pubitemid 36529520)
31. West SK, Munoz B, Mkocha H, Gaydos C, Quinn T (2007) Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Invest Ophthalmol Vis Sci 48: 1492-1497. (Pubitemid 351261330)
32. Ngondi J, Onsarigo A, Matthews F, Reacher M, Brayne C, et al. (2006) Effect of 3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) strategy for trachoma control in southern Sudan: a cross-sectional study. Lancet 368: 589-595. (Pubitemid 44209182)